Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs)

M. A. Dimadi, F. P. Kokkinis, R. Trigidou, P. Demertzis, E. Dimopoulou, S. Kakouros, K. Malagari, D. Bouros (Athens, Lamia, Alexandroupolis, Greece)

Source: Annual Congress 2006 - Pulmonary hypertension: diagnostic tools and therapeutic approaches
Session: Pulmonary hypertension: diagnostic tools and therapeutic approaches
Session type: Thematic Poster Session
Number: 2492
Disease area: Interstitial lung diseases, Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. A. Dimadi, F. P. Kokkinis, R. Trigidou, P. Demertzis, E. Dimopoulou, S. Kakouros, K. Malagari, D. Bouros (Athens, Lamia, Alexandroupolis, Greece). Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs). Eur Respir J 2006; 28: Suppl. 50, 2492

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease
Source: Annual Congress 2012 - Sarcoidosis
Year: 2012



Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008


Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016

Spectrum of interstitial lung diseases (ILDs) and associated prevalence of pulmonary hypertension
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021


Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 27s
Year: 2002

Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008

Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005



Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013


Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 354s
Year: 2006

The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009

Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006

Pulmonary hypertension in different interstitial lung diseases
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012


Pulmonary artery dissection (PAD) in a patient with diffuse interstitial lung disease and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016


Pulmonary hypertension in interstitial lung diseases
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009


Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015


Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013


The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD)
Source: Eur Respir J 2005; 26: Suppl. 49, 560s
Year: 2005

Pulmonary hypertension in interstitial lung disease
Source: Eur Respir J 2008; 31: 1357-1367
Year: 2008



Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD)
Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD
Year: 2011